Some companies ship shoes. This one ships beating hearts. The elevator pitch is to replace the organ on ice with warm, monitored life support that buys time, improves visibility, and boosts the odds the organ gets used. The stock has had its dramatic moments, but the growth is real and the execution drumbeat is getting louder.
Top Picks (Sponsored)
Every market cycle produces a select group of companies that drastically outperform the rest.
The latest screening has pinpointed the 5 Stocks Set to Double, each showing rare traits linked to early stage momentum.
These names carry the same type of indicators that have historically appeared ahead of strong rallies.
Earlier reports featured stocks that delivered +175%, +498%, and +673%.
Get the Free 5 Stocks Set to Double Report.
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Strategic Positioning
TransMedics Group (NASDAQ: TMDX) makes the Organ Care System (OCS), a portable perfusion platform that keeps donor organs warm, oxygenated, and closely watched from pickup to transplant. Think first-class ticket with a cardiologist chaperone, not Styrofoam cooler and a prayer.
Why it matters now:
Bigger donor pool: Warm perfusion stretches travel time, enables better assessment, and can rescue organs that would’ve been tossed on ice.
Razor + service model: This isn’t a one-and-done sale. Every procedure pulls through single-use kits, logistics, and program support. Recurring revenue vibes.
Hospital incentives line up: More usable organs, fewer cancellations, better outcomes. That’s budget-committee catnip.
Category momentum: As centers adopt, they standardize. Standardization begets volume; volume begets margins.
Recent Momentum
Beat-and-raise cadence: A recent print put up ~$143M revenue vs. ~$123M expected and $0.70 EPS, more than 2x consensus. Management lifted full-year revenue guidance to roughly $575M (about 30% YoY), which is spicy for a med-tech mid-cap.
Pattern of upside: Across the last few cycles, revenue growth in the ~37–48% lane with positive surprises has outshone the one infamous miss that taught everyone this name has torque.
Stock check: Up ~86% YTD, still below best levels from last year’s roller coaster, and it moves, so double-digit swings happen. That’s not a bug; it’s the feature.
Street stance: Moderate Buy with targets clustering around $130–$150 and fresh upgrades after the acceleration. Translation: conviction improving, but nobody’s complacent.
Poll: What’s your biggest fear when it comes to emergency savings?
Top Picks (Sponsored)
The next leg of AI growth is set to emerge from advanced data infrastructure, a segment gaining powerful momentum beneath the surface.
Leaders in this space are showing strong operational expansion, increasing government interest, and growing enterprise adoption.
These developments are quietly creating high-probability setups for early movers.
As demand accelerates, positioning inside this sector could produce significant compounding potential.
A FREE report highlights all nine opportunities poised to benefit from this surge.
Download your FREE Report Now.
The Setup You’re Actually Betting On
You’re not betting on macro, the Fed, or soybean futures. You’re betting on adoption curves and execution:
Center expansion: More programs say OCS is standard, not OCS is special. That turns pilots into pipelines.
Utilization lift: The more cases per center, the more disposables per day, the more predictable revenue.
Multi-organ mix: Heart, lung, liver, diversification boosts throughput and smooths seasonality.
Ops maturity: As they scale logistics and staffing, gross margin has room to breathe.
If that flywheel spins, the multiple falls on its own as E grows into P.
Want to make sure you never miss a stock recommendation?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell. Email’s great. Texts are faster.
Action Plan
Treat TMDX like a high-beta healthcare grower with real business guts and real headline risk.
Starter Buy: Buy on red days in the low-120s or below. If it dips into the one-teens on noise, that’s where brave hands usually show up.
Add on Proof: Add if the next call shows >30% YoY revenue, healthy case growth across organs, and sequential gross-margin progress.
Sizing: Keep it 1–2% of equities. It’s the hot sauce, not the stew.
Time Frame: 12–24 months for adoption, capacity, and operating leverage to show through cleanly.
Optional spice: traders sometimes scale around earnings, but investors keep a core position and let compounding do its thing.
Big Gains (Sponsored)
We’re sharing a free copy of our brand-new report: 7 Best Stocks for the Next 30 Days.
For decades, our objective, mathematical stock prediction system has delivered market-beating results, identifying trades with exceptional potential.
This report uncovers the 7 highest-potential stocks from our top-rated selections — fewer than 5% of all stocks qualify.
These could be the most exciting short-term trades in your portfolio.
Act now — download your free copy and be ready for the next move.
[Get the Free Report]
*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.
Valuation Check
You’re paying a growth multiple (P/E ~51), but you’re getting growth-rate fuel most staples can only dream about.
With FY revenue pointed near $575M and margins grinding higher as mix tilts to disposables and ops tighten, the path to de-spook the multiple is simple: volume + execution.
No fancy accounting, just more cases with better unit economics. If they stick the landing on scale and keep guidance inching up, the Street’s model does the re-rating for you.
Catalysts To Watch
Center adds & activations: Fresh hospitals coming online, plus existing centers increasing cadence.
Organ mix: Heart/lung/liver contributions and any color on new indications.
Gross margin: Watch the trend, efficiency, pricing, and disposable utilization should nudge it up.
Guidance cadence: Beat-and-raise is the love language of growth investors.
Coverage/affordability: Reimbursement clarity or cost-offset data that moves committees from pilot to policy.
Ops throughput: Logistics capacity, on-time performance, staffing, unsexy but critical.
Risks
Execution hiccups: This is medicine plus logistics; complexity creates failure points. A stumble can knock the stock off the barstool.
Budget pressure: If hospital capital or staffing tightens, adoption can slow, even with good clinical logic.
Competitive creep: Any rival warm-perfusion platform or protocol advances could nibble share or pricing.
Headline volatility: One miss, one messy quarter, and beta does what beta does.
Concentration: If growth leans too hard on a few high-volume centers, churn or downtime can dent prints.
Mitigation is boring but effective: diversify centers, invest in ops, keep clinicians happy, and let data do the selling.
How To Trade It
Tranches over hero trades: Scale in thirds; don’t marry your first fill.
Use pain rules: If two straight quarters deliver slowing growth and margin backslide with a soft guide, reassess sizing.
Pairing idea: Balance with a steadier healthcare cash-flow name so TMDX’s swings don’t bully your P&L.
Earnings etiquette: Expect fireworks around prints. If you can’t handle pop-and-drop, wait 24–48 hours and buy the hangover.
What A Win Looks Like
30–35%+ revenue growth sustained, with clean beats and raised full-year guide.
Sequential margin lift driven by scale and disposable pull-through.
Broader adoption across geographies and organs, more centers moving TMDX from exception to standard.
Visibility improving: The Street models profitable growth without caveats, and investors start arguing about how big 2027 can be rather than whether 2025 is real.
That combo turns a story stock into a numbers stock, which is where multiple expansion quietly lives.
Final Take
This is a rare mix of mission and margin. The product solves a painfully human problem with a commercially elegant model, stacking disposables and services on innovative hardware. Expect noise. Respect the volatility.
Size it properly. If execution keeps pace with demand, TMDX can keep turning clinical need into shareholder oxygen. In a market obsessed with chips and clicks, this is a reminder that saving time, and maybe lives, can still be a growth business.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
